Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 93 resultados

Gravitate-Health: Gravitate Health Empowering and Equipping Europeans with health information for Active Personal Hea... The Gravitate-Health mission is to equip and empower citizens with digital information tools that make them confident, active, and responsiv...
2020-11-12 - 2025-10-31 | Financiado

H2O: H2O Health Outcomes Observatory ELI LILLY AND COMPANY LTD participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Patients' outcomes and experience of health care can be improved through the systematic capture and use of information from their perspectiv...
2020-09-30 - 2025-09-30 | Financiado

PREMIER: Prioritisation and Risk Evaluation of Medicines in the EnviRonment ELI LILLY AND COMPANY LTD participó en un H2020: H2020-JTI-IMI2-2019-17-two-stage There are around 1900 active pharmaceutical ingredients (APIs) in use, yet the environmental risks of only a small proportion of these has b...
2020-06-24 - 2026-08-31 | Financiado

SOPHIA: Stratification of Obesity Phenotypes to Optimize Future Therapy ELI LILLY AND COMPANY LTD participó en un H2020: H2020-JTI-IMI2-2019-17-two-stage SOPHIA will optimise the future treatment of obesity. The challenge is that clinicians, payers and patients view obesity as a failure of sel...
2020-05-26 - 2025-05-31 | Financiado

INNODIA HARVEST: Translational approaches to disease modifying therapy of type 1 diabetes HARVESTing the fruits of... ELI LILLY AND COMPANY LTD participó en un H2020: H2020-JTI-IMI2-2019-19-single-stage Building on the strong foundations of INNODIA, with its unique, Europe-wide clinical and basic research network for the study of type 1 diab...
2020-04-16 - 2024-04-30 | Financiado

IDEA-FAST: Identifying Digital Endpoints to Assess FAtigue Sleep and acTivities in daily living in Neurodegene... ELI LILLY AND COMPANY LTD participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage Fatigue and sleep disturbances are two common and disabling symptoms that affect patients with neurodegenerative disorders (NDD) and immune-...
2019-12-18 - 2026-04-30 | Financiado

ImmUniverse: Better control and treatment of immune mediated diseases by exploring the universe of microenvironme... ELI LILLY AND COMPANY LTD participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enorm...
2019-12-17 - 2024-12-31 | Financiado

ConcePTION: Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and... ELI LILLY AND COMPANY LTD participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage ConcePTION partners have united around a shared vision that we have a societal obligation to radically and rapidly reduce uncertainty about...
2019-05-06 - 2024-12-31 | Financiado

IMMUcan: Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts ELI LILLY AND COMPANY LTD participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage IMMUcan proposes an inclusive and integrated European immuno-oncology platform. IMMUcan will access high-quality human biological material...
2019-04-23 - 2025-08-31 | Financiado

CARDIATEAM: CARdiomyopathy in type 2 DIAbetes mellitus ELI LILLY AND COMPANY LTD participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage A rapidly evolving epidemic in Type 2 Diabetes (T2DM) is afflicting all ages, sexes and socioeconomic classes which includes serious comorbi...
2019-04-11 - 2026-02-28 | Financiado

TransBioLine: Translational Safety Biomarker Pipeline TransBioLine Enabling development and implementation of n... ELI LILLY AND COMPANY LTD participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage Qualified biomarkers help to optimize drug development and patient safety, yet for the regulatory acceptance of safety biomarkers substantia...
2019-04-08 - 2025-01-31 | Financiado

EBiSC2: EBiSC2 A sustainable European Bank for induced pluripotent Stem Cells ELI LILLY AND COMPANY LTD participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage EBiSC2 builds on the achievements of the European Bank for iPSCs (EBiSC1) in centralising existing capacities across Europe in a unique bank...
2019-02-28 - 2023-02-28 | Financiado

NEURONET: Efficiently Networking European Neurodegeneration Research ELI LILLY AND COMPANY LTD participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage The main aim of NEURONET is to set up an efficient platform to boost synergy and collaboration across the IMI projects of the Neurodegenerat...
2019-02-28 - 2022-08-31 | Financiado

FAIRplus: FAIRplus ELI LILLY AND COMPANY LTD participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage Wide sharing of knowledge and data drives the progression of science. Shared data allows other researchers to reproduce findings and benchma...
2018-12-18 - 2022-12-31 | Financiado

RADAR-AD: Remote Assessment of Disease and Relapse Alzheimer s Disease ELI LILLY AND COMPANY LTD participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage There is an urgent need for novel approaches assessing functional decline in early AD. The main goal of the RADAR-AD project is to develop a...
2018-12-05 - 2023-06-30 | Financiado

EHDEN: European Health Data and Evidence Network ELI LILLY AND COMPANY LTD participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage Europe is generating huge amounts of patient-level information contained in Electronic Health Record (EHR) systems and other types of health...
2018-11-22 - 2024-10-31 | Financiado

TOBeATPAIN: Targeting neuroinflammation to combat pathological pain in neurodegenerative diseases and chronic pa... ELI LILLY AND COMPANY LTD participó en un H2020: H2020-MSCA-ITN-2017 Damage to the central (CNS) and peripheral (PNS) nervous systems causes altered perception of pain (pathological pain) which is a common fea...
2018-07-05 - 2022-07-31 | Financiado

GetReal Initiative: The GetReal Initiative ELI LILLY AND COMPANY LTD participó en un H2020: H2020-JTI-IMI2-2017-11-single-stage The GetReal Initiative brings together partners from the IMI GetReal project to drive the adoption of tools, methodologies and best practice...
2018-06-26 - 2021-04-30 | Financiado

c4c: conect4children COllaborative Network for European Clinical Trials For Children ELI LILLY AND COMPANY LTD participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage Paediatric medicines development is embedded in the European policy, legislation and in the work of the pharmaceutical industry but currentl...
2018-06-22 - 2025-04-30 | Financiado

PARADIGM: Patients Active in Research and Dialogues for an Improved Generation of Medicines Advancing meaning... ELI LILLY AND COMPANY LTD participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage PARADIGM will provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engage...
2018-06-04 - 2020-11-30 | Financiado

Eli Lilly